Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Florence hCA II compound 6
- Development stage
- Unknown
- Lead developer
- Università degli Studi di Firenze
01
Overview
Univ. of Florence hCA II compound 6: sourced facts only. name: "Conversely, introduction of a 4-sulfamoylbenzoyl group on the piperazine nitrogen atom switched the activity from activation to inhibition, yielding compound 6 as a potent inhibitor of hCA II." [PMID:42400094]; target: "Conversely, introduction of a 4-sulfamoylbenzoyl group on the piperazine nitrogen atom switched the activity from activation to inhibition, yielding compound 6 as a potent inhibitor of hCA II." [PMID:42400094]; developer: "Department NEUROFARBA, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Sesto Fiorentino, Italy." [PMID:42400094]
02
Targets
CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on Univ. of Florence hCA II compound 6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Florence hCA II compound 6.